

Reference Number: FOIAH2324/019
From: Commercial
Date: 13 April 2023
Subject: Use of new biologic and targeted medications within dermatology and respiratory medicine

Q1 How many patients were treated in March 2023 (or latest available month) by the Dermatology department with the following drugs:

- a. Abrocitinib (Cibinqo)
- b. Baricitinib (Olumiant)
- c. Dupilumab (Dupixent)
- d. Omalizumab (Xolair)
- e. Tralokinumab (Adtralza)
- f. Upadacitinib (Rinvoq)

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

Q2 How many patients were treated in March 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- a. Benralizumab (Fasenra)
- b. Dupilumab (Dupixent)
- c. Mepolizumab (Nucala)
- d. Omalizumab (Xolair)
- e. Reslizumab (Cinqaero)
- f. Tezepelumab (Tezspire)

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.